Sun Pharmaceutical Industries Limited has informed the Exchange about change in Key Managerial Personnel - Chief Financial Officer
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty 100 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharmaceutical Industries has announced a planned CFO transition. The current CFO, Mr. C S Muralidharan (EVP – Finance & Accounts), will superannuate (retire) effective 1 July 2025. Ms. Jayashree Satagopan has been appointed as his successor and will join as CFO (Designate) on 9 May 2025, formally taking over as CFO from 1 July 2025. The Board approved her appointment based on recommendations of the Nomination & Remuneration Committee and Audit Committee. Ms. Satagopan is a CA, CMA, and CS with over 30 years of experience, most recently serving as President Corporate and CFO at Coromandel International (Murugappa group), with prior stints at PI Industries, International Paper, GE Healthcare, Ford India, and Ashok Leyland. The Board recorded appreciation for Mr. Muralidharan's contributions spanning acquisitions, integration, finance transformation, and sustainability reporting.
This is an orderly, pre-planned leadership change with a successor already in place, so the stock impact is likely minimal. The transition brings in a seasoned CFO with diverse cross-industry experience, which investors may view positively for governance continuity and financial oversight.